ASX 50

The copper price has completely retraced its March-May rally. Major broker Macquarie considers what’s next for Dr Copper.

Australia's biggest healthcare stock disappointed on guidance for FY25, sending its share price south.

Data doesn't always uncover the granular nuances of the economy. That's where company earnings can help.

For background information about this A1-quality company, I previewed REA Group’s (ASX:REA) latest results here, wrote about why I believe REA Group is one of...

A handful of stock ideas that could prove useful should the weather turn nasty.

Ray David from Blackwattle Investment Partners discusses the transformation underway at News Corp led by CEO Robert Thomson.

Markets seesaw in wild week: S&P 500's worst day since 2022, Japan's whiplash rally, and more as investors ride volatility rollercoaster.

Read on to find the ratings, consensus price targets, and FNArena insights on each stock covered.

And four narratives that will be tested this reporting season...

We look at five of the biggest developments across global markets for the week ending 9 August 2024

It's been labelled an "incredible business" and an ASX "market champion". But can REA Group surpass the lofty earnings expectations?

Despite challenges like inflation and finance costs, Transurban will retain its position in The Montgomery Fund’s portfolio.

Are these ASX companies the investing equivalent to some of the world's great Olympians? I'll take a look.

There are several pieces of credible evidence to support the case for a price bounce, which would be good news for fast-growing Patriot.

Wilsons Advisory’s Melissa Benson and Shane Storey share their insights in the final part of the biotech mini-series.

Aka the "lazy" way to build up your share portfolio.

From digging for unloved value to discovering the best founder-led companies, these investors have different views on how to generate alpha.

The most important month of the investing year is here - and the stakes are very high.

ResMed (ASX:RMD) reported its June quarter and full year results after the U.S. market closed on Friday morning. The company met consensus expectations for both...

Find out in this episode of Buy Hold Sell - featuring Henry Jennings from Marcus Today and James Gerrish from Market Matters.

ASX Reporting Season begins with Rio Tinto and ResMed surging. The RBA may pause rate hikes after lower inflation. Fed hints at rate cuts.

It's been a wild ride for ResMed over the past couple of years and while there might be further volatility, things are back on track

And why it's the points that you win that matter.

As BHP/Lundin lock in their South American prize, former geologist, James Cooper discusses the opportunity cost for junior mining investors